AlloVir logo

AlloVirNASDAQ: ALVR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 July 2020

Next earnings report:

01 November 2024

Last dividends:

N/A

Next dividends:

N/A
$109.60 M
-93%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector
-84%vs. 3y high
38%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:10:10 GMT
$0.95+$0.04(+4.88%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ALVR Latest News

Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm
globenewswire.com16 September 2024 Sentiment: NEUTRAL

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of AlloVir, Inc. (NASDAQ: ALVR) breached their fiduciary duties to shareholders.

Are Medical Stocks Lagging AlloVir (ALVR) This Year?
Zacks Investment Research29 January 2024 Sentiment: POSITIVE

Here is how AlloVir, Inc. (ALVR) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)
Zacks Investment Research12 January 2024 Sentiment: POSITIVE

AlloVir, Inc. (ALVR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts
InvestorPlace05 January 2024 Sentiment: NEGATIVE

AlloVir (NASDAQ: ALVR ) layoffs are in the news as the clinical-stage cell therapy company announced a massive number of job cuts. AlloVir has revealed that a new round of layoffs will have it cutting 95% of its workforce.

AlloVir shedding 95% of its staff after discontinuing T cell therapy trial
Market Watch04 January 2024 Sentiment: NEGATIVE

AlloVir Inc. ALVR, +5.02%, a developer of cell therapies intended to treat viral diseases, said Thursday that its board had approved a roughly 95% reduction to its staff, following an announcement last month that it would discontinue three clinical trials on its lead T cell therapy posoleucel. The company, in a filing, said the board approved the cuts on Jan. 1, and that the cuts were intended to “preserve capital.

AlloVir's stock suffers record plunge toward a record low after trials on T cell therapy
Market Watch22 December 2023 Sentiment: NEGATIVE

Shares of AlloVir Inc. ALVR, -66.75% plummeted 66.6% toward their first-ever close below $1 on heavy volume in afternoon trading Friday, after the immunotherapy company decided to discontinue the Phase 3 trials on posoleucel, a T cell therapy targeting a number of pathogens in immunocompromised people, citing “futility.” The stock, which was the biggest decliner among those listed on major U.S. exchanges, is headed for its biggest decline since going public in July 2020.

Why AlloVir Stock Dropped Today
The Motley Fool21 September 2023 Sentiment: NEGATIVE

AlloVir stock fell today given concerns over potential selling pressure from a recent lock-up expiration. The lock-up agreement was related to a new share issuance in June 2023.

5 Stocks With Rising P/E to Bet on for Solid Gains
Zacks Investment Research07 August 2023 Sentiment: POSITIVE

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Crocs (CROX), AlloVir (ALVR), Arcadia Biosciences (RKDA), The Duckhorn Portfolio (NAPA) and Genuine Parts (GPC).

5 Top-Ranked Stocks With Rising P/E Worth Investing In
Zacks Investment Research21 July 2023 Sentiment: POSITIVE

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Planet Fitness (PLNT), AlloVir (ALVR), Entergy (ETR), The Duckhorn Portfolio (NAPA) and Genuine Parts (GPC).

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
MarketBeat13 July 2023 Sentiment: POSITIVE

In recent Securities & Exchange Commission filings, Gilead Sciences Inc. NASDAQ: GILD revealed that it had purchased significant stakes in AlloVir Inc. NASDAQ: ALVR and Arcus Biosciences Inc. NYSE: RCUS.

What type of business is AlloVir?

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

What sector is AlloVir in?

AlloVir is in the Healthcare sector

What industry is AlloVir in?

AlloVir is in the Biotechnology industry

What country is AlloVir from?

AlloVir is headquartered in United States

When did AlloVir go public?

AlloVir initial public offering (IPO) was on 30 July 2020

What is AlloVir website?

https://www.allovir.com

Is AlloVir in the S&P 500?

No, AlloVir is not included in the S&P 500 index

Is AlloVir in the NASDAQ 100?

No, AlloVir is not included in the NASDAQ 100 index

Is AlloVir in the Dow Jones?

No, AlloVir is not included in the Dow Jones index

When was AlloVir the previous earnings report?

No data

When does AlloVir earnings report?

The next expected earnings date for AlloVir is 01 November 2024